Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399527 | 0.85 | CYP1A2 (0.57) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL9604572 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP2D6MAPK1 | |
| Hydrochloric Acid SCHEMBL8169253 | 0.75 | CYP1A2 (0.50) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL8970970 | 0.75 | YTHDC1 (0.66) | — | |
| SCHEMBL9120 | 0.75 | ADORA2A (0.59) | — | |
| SCHEMBL9705702 | 0.75 | CYP1A2 (0.62) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL21539317 | 0.73 | CYP1A2 (0.51) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL754049 | 0.72 | ADORA2A (0.60) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL12410753 | 0.72 | PI4KA (0.60) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL12498653 | 0.72 | CYP1A2 (0.78) | CYP1A2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056478-A1 | iRNA COMPOSITIONS AND METHODS FOR TARGETING ANGPTL7 | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023288045-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | LUMINEX INTERNATIONAL (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | CYP1A2 3361/4885CYP2D6 4415/4885MAPK1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.